Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 5Uterine Neoplasms 2Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Neoplasms, Unknown Primary 2Lung Neoplasms 2Carcinoma 2Urologic Neoplasms 1Urogenital Neoplasms 1Unresectable Stage III NSCLC 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Penile Neoplasms 1Pathologic Complete Response 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Male Urogenital Diseases 1Genital Neoplasms, Female 1Genital Diseases, Female 1First-line Advanced NSCLC Patients 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Endocrine System Diseases 1

Interventions

Pemetrexed 1Immune Checkpoint Inhibitors 1Drug Therapy 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × First-line Advanced NSCLC Patients × CP protocol × Clear all
NCT07171606 2025-12-18

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 2 Recruiting
240 enrolled
Thoracic

First-line Advanced NSCLC Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡